Towards selectively modulating mineralocorticoid receptor function: Lessons from other systems

Molecular and Cellular Endocrinology

Volumn 217, Issue 1-2, 2004, Pages 151-165

  Baxter, John D ^a   Funder, John W ^b   Apriletti, James W ^a   Webb, Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Mineralocorticoid receptor; Thyroid hormone receptor

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; CELL NUCLEUS RECEPTOR; EPLERENONE; HYDROCORTISONE; LIGAND; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

BINDING AFFINITY; CONFERENCE PAPER; CONFORMATION; CRYSTAL STRUCTURE; DRUG EFFECT; ENDOCRINE DISEASE; HORMONE BINDING; LIGAND BINDING; MOLECULE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; THYROID GLAND; X RAY CRYSTALLOGRAPHY;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANTI-INFLAMMATORY AGENTS; CRYSTALLOGRAPHY, X-RAY; EPITHELIUM; HYDROCORTISONE; MYOCYTES, CARDIAC; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; RECEPTORS, THYROID HORMONE; SIGNAL TRANSDUCTION; SPIRONOLACTONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2342544131     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2003.10.044     Document Type: Conference Paper

References (142)

1. An J., Ribeiro R.C., Webb P., Gustafsson J.A., Kushner P.J., Baxter J.D., Leitman D.C. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc. Natl. Acad. Sci. U.S.A. 96:1999;15161-15166
2. Arriza J.L., Weinberger C., Cerelli G., Glaser T.M., Handelin B.L., Housman D.E., Evans R.M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 237:1987;268-275
3. Arriza J.L., Simerly R.B., Swanson L.W., Evans R.M. The neuronal mineralocorticoid receptor as a mediator of glucocorticoid response. Neuron. 1:1988;887-900
4. Ashburner M. Induction of puffs in polytene chromosomes of in vitro cultured salivary glands of Drosophila melanogaster by ecdysone and echysone analogues. Nat. New Biol. 230:1971;222-224
5. Ballard P.L., Baxter J.D., Higgins S.J., Rousseau G.G., Tomkins G.M. General presence of glucocorticoid receptors in mammalian tissues. Endocrinology. 94:1974;998-1002
6. Baxter J.D., Tomkins G.M. The relationship between glucocorticoid binding and tyrosine aminotransferase induction in hepatoma tissue culture cells. Proc. Natl. Acad. Sci. U.S.A. 65:1970;709-715
7. Baxter J.D., Tomkins G.M. Specific cytoplasmic glucocorticoid hormone receptors in hepatoma tissue culture cells. Proc. Natl. Acad. Sci. U.S.A. 68:1971;932-937
8. Baxter J.D., Rousseau G.G., Benson M.C., Garcea R.L., Ito J., Tomkins G.M. Role of DNA and specific cytoplasmic receptors in glucocorticoid action. Proc. Natl. Acad. Sci. U.S.A. 69:1972;1892-1896
9. Baxter J.D., Dillmann W.H., West B.L., Huber R., Furlow J.D., Fletterick R.J., Webb P., Apriletti J.W., Scanlan T.S. Selective modulation of thyroid hormone receptor action. J. Steroid Biochem. Mol. Biol. 76:2001;31-42
10. Baxter J.D., Goede P., Apriletti J.W., West B.L., Feng W., Mellstrom K., Fletterick R.J., Wagner R.L., Kushner P.J., Ribeiro R.C.J., Webb P., Scanlan T.S., Nilsson S. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology. 143:2002;517-524
11. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A., Polly M.L., McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63:2003;1791-1800
12. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α Nature. 375:1995;377-382
13. Brown M.A., Cramp H.A., Zammit V.C., Whitworth J.A. Primary hyperaldosteronism: a missed diagnosis in 'essential hypertensives'? Aust. N. Z. J. Med. 26:1996;533-538
14. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 389:1997;753-758
15. Carlstedt-Duke J., Okret S., Wrange O., Gustafsson J.A. Immunochemical analysis of the glucocorticoid receptor: identification of a third domain separate from the steroid-binding and DNA-binding domains. Proc. Natl. Acad. Sci. U.S.A. 79:1982;4260-4264
16. Cato, A.C.B., Mink, S., Hartig, E., 1991. Gene activation mediated by glucocorticoid and mineralocorticoid receptors: the role of the steroid ligand. In: Bonvalet, J.P., Farman, N., Lombes, M., Rafestin-Oblin, M.E. (Eds.), Aldosterone: Fundamental Aspects. Colloque INSERM/John Libbey Eurotext Ltd., Paris, pp. 23-32.
17. Chiellini G., Apriletti J.W., Yoshihara H.A.I., Baxter J.D., Ribeiro R.C., Scanlan T.S. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem. Biol. 5:1998;299-306
18. Conn J.W. Primary aldosteronism, a new clinical syndrome. J. Lab. Clin. Med. 45:1955;6-17
19. Conn J.W. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome, 1954. J. Lab. Clin. Med. 116:1990;253-267
20. Conn, J.W., Cohen, E.L., Rovner, D.R., 1985. In: Conn, J.W., Cohen, E.L., Rovner, D.R. (Eds.), Landmark article October 19, 1964: suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. JAMA 253, 558-566.
21. Darimont B.D., Wagner R.L., Apriletti J.W., Stallcup M.R., Kushner P.J., Baxter J.D., Fletterick R.J., Yamamoto K.R. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 12:1998;3343-3356
22. Edelman I.S., Fimognari G.M. On the biochemical mechanism of action of aldosterone. Rec. Prog. Horm. Res. 24:1968;1-44
23. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895
24. Fagart J., Wurtz J.M., Souque A., Hellal-Levy C., Moras D., Rafestin-Oblin M.E. Antagonism in the human mineralocorticoid receptor. EMBO J. 17:1998;3317-3325
25. Fawell S.E., Lees J.A., White R., Parker M.G. Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell. 60:1990;953-962
26. Feldman D., Funder J.W., Edelman I.S. Evidence for a new class of corticosterone receptors in the rat kidney. Endocrinology. 92:1973;1429-1441
27. Feng W., Ribeiro R.C.J., Wagner R.L., Nguyen H., Apriletti J.W., Fletterick R.J., Baxter J.D., Kushner P.J., West B.L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 280:1998;1747-1749
28. Fiebeler A., Schmidt F., Muller D.N., Park J.K., Dechend R., Bieringer M., Shagdarsuren E., Breu V., Haller H., Luft F.C. Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension. 37:2001;787-793
29. Funder J.W. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu. Rev. Med. 48:1997;231-240
30. Funder J.W. Aldosterone action: fact, failure and the future. Clin. Exp. Pharmacol. Physiol. Suppl. 25:1998;S47-S50
31. Funder J.W. Eplerenone, a new mineralocorticoid antagonist: in vitro and in vivo studies. Curr. Opin. Endocrinol. Diabet. 7:2000;138-142
32. Funder J.W. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Am. Heart J. 144:2002;S8-S11
33. Funder J.W., Feldman D., Edelman I.S. Specific aldosterone binding in rat kidney and parotid. J. Steroid Biochem. 3:1972;209-218
34. Funder J.W., Pearce P.T., Myles K., Roy L.P. Apparent mineralocorticoid excess, pseudohypoaldosteronism, and urinary electrolyte excretion: toward a redefinition of mineralocorticoid action. FASEB J. 4:1990;3234-3238
35. Funder J., Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology. 137:1996;5264-5268
36. Funder J.W., Pearce P.T., Smith R., Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor mediated. Science. 242:1988;583-585
37. Geistlinger T.R., Guy R.K. An inhibitor of the interaction of thyroid hormone receptor β and glucocorticoid interacting protein 1. J. Am. Chem. Soc. 123:2001;1525-1526
38. Gittler R.D., Fajans S.S. Primary aldosteronism (Conn's syndrome). J. Clin. Endocrinol. Metab. 80:1995;3438-3441
39. Glass C.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:2000;121-141
40. Gomez-Sanchez E.P., Venkataraman M.T., Thwaites D., Fort C. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. Am. J. Physiol. 258:1990;E649-E653
41. Gordon R.D., Ziesak M.D., Tunny T.J., Stowasser M., Klemm S.A. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin. Exp. Pharmacol. Physiol. 20:1993;296-298
42. Gordon R.D., Stowasser M., Tunny T.J., Klemm S.A., Rutherford J.C. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol. 21:1994;315-318
43. Gothe S., Wang Z., Ng L., Kindblom J.M., Barros A.C., Ohlsson C., Vennstrom B., Forrest D. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes Dev. 13:1999;1329-1341
44. Grover, G.J., Mellstrom, K., Ye, L., Malm, J., Li, Y.L., Bladh, L.G., Sleph, P.G., Smith, M.A., George, R., Vennstrom, B., Mookhtiar, K., Horvath, R., Speelman, J., Egan, D., Baxter, J.D., 2003. Selective thyroid hormone receptor-β activation: a strategy for reduction of weight, cholesterol, and lipoprotein(a) with reduced cardiovascular liability. Proc. Natl. Acad. Sci. U.S.A., Jul 29 [Epub ahead of print].
45. He B., Wilson E.M. The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol. Genet. Metab. 75:2002;293-298
46. Hiramatsu K., Yamada T., Yukimura Y., Komiya I., Ichikawa K., Ishihara M., Nagata H., Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch. Intern. Med. 141:1981;1589-1593
47. Hollenberg S.M., Weinberger C., Ong E.S., Cerelli G., Oro A., Lebo R., Thompson E.B., Rosenfeld M.G., Evans R.M. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 318:1985;635-641
48. Hollenberg A.N., Monden T., Wondisford F.E. Ligand-independent and ligand-dependent functions of thyroid hormone receptor isoforms depend upon their distinct amino termini. J. Biol. Chem. 270:1995;14274-14280
49. Iniguez-Lluhi J.A., Pearce D. A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy. Mol. Cell. Biol. 20:2000;6040-6050
50. Jakacka M., Ito M., Weiss J., Chien P.Y., Gehm B.D., Jameson J.L. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J. Biol. Chem. 276:2001;13615-13621
51. Jensen, E.V., Jacobson, H.L., 1960. Fate of steroidal estrogen in target tissues. In: Pineus, G., Vollmer, E.P. (Eds.), Biological Activities of Steroids in Relation to Cancer: Proceedings. Academic Press, New York, pp. 161-178.
52. Jensen E.V., Suzuki T., Kawashima T., Stumpf W.E., Jungblut P.W., DeSombre E.R. A two-step mechanism for the interaction of estradiol with rat uterus. Proc. Natl. Acad. Sci. U.S.A. 59:1968;632-638
53. Jepsen K., Hermanson O., Onami T.M., Gleiberman A.S., Lunyak V., McEvilly R.J., Kurokawa R., Kumar V., Liu F., Seto E., Hedrick S.M., Mandel G., Glass C.K., Rose D.W., Rosenfeld M.G. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell. 102:2000;753-763
54. King W.J., Greene G.L. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature. 307:1984;745-747
55. Kitagawa H., Yanagisawa J., Fuse H., Ogawa S., Yogiashi Y., Okuno A., Nagasawa H., Nakajima T., Matsumoto T., Kato S. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol. Cell. Biol. 22:2002;3698-3706
56. Kotaja N., Karvonen U., Janne O.A., Palvimo J.J. PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cell. Biol. 22:2002;5222-5234
57. Krozowski Z.S., Funder J.W. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc. Natl. Acad. Sci. U.S.A. 80:1983;6056-6060
58. Kumar R., Thompson E.B. Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions. Mol. Endocrinol. 17:2003;1-10
59. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., Webb P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74:2000;311-317
60. Lan N.C., Matulich D.T., Morris J.A., Baxter J.D. Mineralocorticoid receptor-like aldosterone-binding protein in cell culture. Endocrinology. 109:1981;1963-1970
61. Lazar M.A. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr. Rev. 14:1993;184-193
62. Liden J., Delaunay F., Rafter I., Gustafsson J., Okret S. A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. J. Biol. Chem. 272:1997;21467-21472
63. Lim P.O., Rodgers P., Cardale K., Watson A.D., MacDonald T.M. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet. 353:1999;40
64. Lim W., Nguyen N.H., Yang H.Y., Scanlan T.S., Furlow J.D. A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J. Biol. Chem. 277:2002;35664-35670
65. Liu W., Wang J., Sauter N.K., Pearce D. Steroid receptor heterodimerization demonstrated in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 92:1995;12480-12484
66. Liu W., Wang J., Yu G., Pearce D. Steroid receptor transcriptional synergy is potentiated by disruption of the DNA-binding domain dimer interface. Mol. Endocrinol. 10:1996;1399-1406
67. Loh K.C., Koay E.S., Khaw M.C., Emmanuel S.C., Young W.F. Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J. Clin. Endocrinol. Metab. 85:2000;2854-2859
68. Lombes M., Kenouch S., Souque A., Farman N., Rafestin-Oblin M.E. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase. Endocrinology. 135:1994;834-840
69. Maglich, J.M., Sluder, A., Guan, X., Shi, Y., McKee, D.D., Carrick, K., Kamdar, K., Willson, T.M., Moore, J.T., 2001. Comparison of complete nuclear receptor sets from the human. Caenorhabditis elegans and Drosophila genomes. Genome Biol. 2, research0029.0021-research0029.0027.
70. Marimuthu A., Feng W., Tagami T., Nguyen H., Jameson J.L., Fletterick R.J., Baxter J.D., West B.L. TR surfaces and conformations required to bind nuclear receptor corepressor. Mol. Endocrinol. 16:2002;271-286
71. Martinez D.V., Rocha R., Matsumura M., Oestreicher E., Ochoa-Maya M., Roubsanthisuk W., Williams G.H., Adler G.K. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension. 39:2002;614-618
72. McDonnell D.P., Chang C.Y., Norris J.D. Development of peptide antagonists that target estrogen receptor-cofactor interactions. J. Steroid Biochem. Mol. Biol. 74:2000;327-335
73. McKenna N.J., O'Malley B.W. From ligand to response: generating diversity in nuclear receptor coregulator function. J. Steroid Biochem. Mol. Biol. 74:2000;351-356
74. McKenna T.J., Sequeira S.J., Heffernan A., Chambers J., Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin- aldosterone axis, including primary hyperaldosteronism. J. Clin. Endocrinol. Metab. 73:1991;952-957
75. McMahon E.G. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol. 1:2001;190-196
76. McMahon E.G. Eplerenone, a new selective aldosterone blocker. Curr. Pharm. Des. 9:2003;1065-1075
77. Means A.R., Comstock J.P., Rosenfeld G.C., O'Malley B.W. Ovalbumin messenger RNA of chick oviduct: partial characterization, estrogen dependence, and translation in vitro. Proc. Natl. Acad. Sci. U.S.A. 69:1972;1146-1150
78. Miesfeld R., Okret S., Wikstrom A.C., Wrange O., Gustafsson J.A., Yamamoto K.R. Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells. Nature. 312:1984;779-781
79. Munck A., Brinck-Johnsen T. Specific and nonspecific physicochemical interactions of glucocorticoids and related steroids with rat thymus cells in vitro. J. Biol. Chem. 243:1968;5556-5565
80. Myles K., Funder J.W. Type I (mineralocorticoid) receptors in the guinea pig. Am. J. Physiol. 267:1994;E268-E272
81. Naray-Fejes-Toth A., Fejes-Toth G. Glucocorticoid receptors mediate mineralocorticoid-like effects in cultured collecting duct cells. Am. J. Physiol. 259:1990;F672-F678
82. Nguyen N.H., Apriletti J.W., Cunha Lima S.T., Webb P., Baxter J.D., Scanlan T.S. Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J. Med. Chem. 45:2002;3310-3320
83. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor gamma. Nature. 395:1998;137-143
84. Norris, J.D., Chang, C., McDonnell, D.P., 2001. Estrogen receptor-cofactor interactions as targets for novel drug discovery. In: Ernst Schering Research Found Workshop, pp. 181-201.
85. Pearce D., Yamamoto K.R. Mineralocorticoid and glucocorticoid receptor activities distinguished by nonreceptor factors at a composite response element. Science. 259:1993;1161-1165
86. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341:1999;709-717
87. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348:2003;1309-1321
88. Poukka H., Aarnisalo P., Karvonen U., Palvimo J.J., Janne O.A. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J. Biol. Chem. 274:1999;19441-19446
89. Poukka H., Karvonen U., Janne O.A., Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. U.S.A. 97:2000;14145-14150
90. Pratt W.B., Gehring U., Toft D.O. Molecular chaperoning of steroid hormone receptors. EXS. 77:1996;79-95
91. Qin W., Rudolph A.E., Bond B.R., Rocha R., Blomme E.A., Goellner J.J., Funder J.W., McMahon E.G. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ. Res. 93:2003;69-76
92. Reichardt H.M., Kaestner K.H., Tuckermann J., Kretz O., Wessely O., Bock R., Gass P., Schmid W., Herrlich P., Angel P., Schutz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell. 93:1998a;531-541
93. Reichardt H.M., Kaestner K.H., Wessely O., Gass P., Schmid W., Schutz G. Analysis of glucocorticoid signalling by gene targeting. J. Steroid Biochem. Mol. Biol. 65:1998b;111-115
94. Renaud J.P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature. 378:1995;681-689
95. Ribeiro R.C.J., Kushner P.J., Baxter J.D. The nuclear hormone receptor gene superfamily. Annu. Rev. Med. 46:1995;443-453
96. Ribeiro R.C., Apriletti J.W., Wagner R.L., Feng W., Kushner P.J., Nilsson S., Scanlan T.S., West B.L., Fletterick R.J., Baxter J.D. X-ray crystallographic and functional studies of thyroid hormone receptor. J. Steroid Biochem. Mol. Biol. 65:1998a;133-141
97. Ribeiro R.C.J., Apriletti J.W., Wagner R.L., West B.L., Feng W., Huber R., Kushner P.J., Nilsson S., Scanlan T.S., Fletterick R.J., Schaufele F., Baxter J.D. Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies. Rec. Prog. Horm. Res. 53:1998b;351-394
98. Ribeiro R.C., Feng W., Wagner R.L., Costa C.H., Pereira A.C., Apriletti J.W., Fletterick R.J., Baxter J.D. Definition of the surface in the thyroid hormone receptor ligand binding domain for association as homodimers and heterodimers with retinoid X receptor. J. Biol. Chem. 276:2001;14987-14995
99. Rocha R., Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann. N. Y. Acad. Sci. 970:2002;89-100
100. Rocha R., Williams G.H. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs. 62:2002;723-731
101. Rocha R., Stier C.T. Jr., Kifor I., Ochoa-Maya M.R., Rennke H.G., Williams G.H., Adler G.K. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 141:2000;3871-3878
102. Rocha R., Martin-Berger C.L., Yang P., Scherrer R., Delyani J., McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 143:2002a;4828-4836
103. Rocha R., Rudolph A.E., Frierdich G.E., Nachowiak D.A., Kekec B.K., Blomme E.A., McMahon E.G., Delyani J.A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 283:2002b;H1802-H1810
104. Rogerson F.M., Fuller P.J. Mineralocorticoid action. Steroids. 65:2000;61-73
105. Rogerson F.M., Fuller P.J. Interdomain interactions in the mineralocorticoid receptor. Mol. Cell. Endocrinol. 200:2003;45-55
106. Rousseau G., Baxter J.D., Funder J.W., Edelman I.S., Tomkins G.M. Glucocorticoid and mineralocorticoid receptors for aldosterone. J. Steroid Biochem. 3:1972;219-227
107. Rupprecht R., Arriza J.L., Spengler D., Reul J.M., Evans R.M., Holsboer F., Damm K. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol. Endocrinol. 7:1993;597-603
108. Sadar M.D., Hussain M., Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr. Relat. Cancer. 6:1999;487-502
109. Sato A., Funder J.W. High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes. Endocrinology. 137:1996;4145-4153
110. Schaumburg B.P., Bojesen E. Specificity and thermodynamic properties of the corticosteroid binding to a receptor of rat thymocytes in vitro. Biochim. Biophys. Acta. 170:1968;172-188
111. Shang Y., Brown M. Molecular determinants for the tissue specificity of SERMs. Science. 295:2002;2465-2468
112. Shemshedini L., Knauthe R., Sassone-Corsi P., Pornon A., Gronemeyer H. Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors. EMBO J. 10:1991;3839-3849
113. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., Greene G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 95:1998;927-937
114. Smith R.E., Little P.J., Maguire J.A., Stein-Oakley A.N., Krozowski Z.S. Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme. Clin. Exp. Pharmacol. Physiol. 23:1996;549-551
115. Starr D.B., Matsui W., Thomas J.R., Yamamoto K.R. Intracellular receptors use a common mechanism to interpret signaling information at response elements. Genes Dev. 10:1996;1271-1283
116. Suthers M.B., Pressley L.A., Funder J.W. Glucocorticoid receptors: evidence for a second, non-glucocorticoid binding site. Endocrinology. 99:1976;260-269
117. Swaneck G.E., Highland E., Edelman I.S. Stereospecific nuclear and cytosol aldosterone-binding proteins of various tissues. Nephron. 6:1969;297-316
118. Swaneck G.E., Chu L.L., Edelman I.S. Stereospecific binding of aldosterone to renal chromatin. J. Biol. Chem. 245:1970;5382-5389
119. Szapary D., Huang Y., Simons S.S. Jr. Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression. Mol. Endocrinol. 13:1999;2108-2121
120. Teyssier C., Belguise K., Galtier F., Chalbos D. Characterization of the physical interaction between estrogen receptor alpha and JUN proteins. J. Biol. Chem. 276:2001;36361-36369
121. Trost S.U., Swanson E., Gloss B., Wang-Iverson D.B., Zhang H., Volodarsky T., Grover G.J., Baxter J.D., Chiellini G., Scanlan T.S., Dillmann W.H. The thyroid hormone receptor-β-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology. 141:2000;3057-3064
122. van Beeren H.C., Bakker O., Wiersinga W.M. Desethylamiodarone interferes with the binding of co-activator GRIP-1 to the beta 1-thyroid hormone receptor. FEBS Lett. 481:2000;213-216
123. Wagner R.L., Apriletti J.W., McGrath M.E., West B.L., Baxter J.D., Fletterick R.J. A structural role for hormone in the thyroid hormone receptor. Nature. 378:1995;690-697
124. Wagner B.L., Norris J.D., Knotts T.A., Weigel N.L., McDonnell D.P. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol. Cell. Biol. 18:1998;1369-1378
125. Wagner R.L., Huber B.R., Shiau A.K., Kelly A., Cunha Lima S.T., Scanlan T.S., Apriletti J.W., Baxter J.D., West B.L., Fletterick R.J. Hormone selectivity in thyroid hormone receptors. Mol. Endocrinol. 15:2001;398-410
126. Wakeling A.E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr. Relat. Cancer. 7:2000;17-28
127. Weatherman R.V., Fletterick R.J., Scanlan T.S. Nuclear-receptor ligands and ligand-binding domains. Annu. Rev. Biochem. 68:1999;559-581
128. Webb P., Lopez G.N., Uht R.M., Kushner P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9:1995;443-456
129. Webb P., Nguyen N.H., Chiellini G., Yoshihara H.A., Cunha Lima S.T., Apriletti J.W., Ribeiro R.C., Marimuthu A., West B.L., Goede P., Mellstrom K., Nilsson S., Kushner P.J., Fletterick R.J., Scanlan T.S., Baxter J.D. Design of thyroid hormone receptor antagonists from first principles. J. Steroid Biochem. Mol. Biol. 83:2002;59-73
130. Webb P., Nguyen P., Kushner P.J. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. J. Biol. Chem. 278:2003;6912-6920
131. Weinberger M.H., Roniker B., Krause S.L., Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. 15:2002;709-716
132. Welshons W.V., Lieberman M.E., Gorski J. Nuclear localization of unoccupied oestrogen receptors. Nature. 307:1984;747-749
133. Wilkinson J.R., Towle H.C. Identification and characterization of the AF-1 transactivation domain of thyroid hormone receptor β1. J. Biol. Chem. 272:1997;23824-23832
134. Wilson R.C., Harbison M.D., Krozowski Z.S., Funder J.W., Shackleton C.H., Hanauske-Abel H.M., Wei J.Q., Hertecant J., Moran A., Neiberger R.E. Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 80:1995a;3145-3150
135. Wilson R.C., Krozowski Z.S., Li K., Obeyesekere V.R., Razzaghy-Azar M., Harbison M.D., Wei J.Q., Shackleton C.H., Funder J.W., New M.I. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J. Clin. Endocrinol. Metab. 80:1995b;2263-2266
136. Wrange O., Gustafsson J.A. Separation of the hormone- and DNA-binding sites of the hepatic glucocorticoid receptor by means of proteolysis. J. Biol. Chem. 253:1978;856-865
137. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., McKee D.D., Galardi C.M., Plunket K.D., Nolte R.T., Parks D.J., Moore J.T., Kliewer S.A., Willson T.M., Stimmel J.B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα Nature. 415:2002;813-817
138. Yen P.M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 81:2001;1097-1142
139. Young M., Fullerton M., Dilley R., Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Invest. 93:1994;2578-2583
140. Young W.F. Jr. Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology. 144:2003;2208-2213
141. Young M.J., Funder J.W. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am. J. Physiol. 271:1996;E883-E888
142. Young M.J., Funder J.W. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. J. Hypertens. 20:2002;1465-1468